Format

Send to

Choose Destination
JAMA Netw Open. 2018 Sep 7;1(5):e182327. doi: 10.1001/jamanetworkopen.2018.2327.

Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms: A Systematic Review and Meta-analysis.

Su KP1,2,3, Tseng PT4, Lin PY5,6,7, Okubo R8, Chen TY9,10,11, Chen YW12, Matsuoka YJ3,8.

Author information

1
Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan.
2
Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan.
3
College of Medicine, China Medical University, Taichung, Taiwan.
4
WinShine Clinics in Specialty of Psychiatry, Kaohsiung City, Taiwan.
5
Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
6
Chang Gung University College of Medicine, Kaohsiung, Taiwan.
7
Institute for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
8
Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan.
9
Department of Psychiatry, Tri-Service General Hospital, Taipei, Taiwan.
10
School of Medicine, National Defense Medical Center, Taipei, Taiwan.
11
Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan.
12
Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung, Taiwan.

Abstract

Importance:

No systematic review or meta-analysis has assessed the efficacy of omega-3 polyunsaturated fatty acids (PUFAs) for anxiety.

Objective:

To evaluate the association of anxiety symptoms with omega-3 PUFA treatment compared with controls in varied populations.

Data Sources:

PubMed, Embase, ProQuest, ScienceDirect, Cochrane Library, ClinicalKey, Web of Science, and ClinicalTrials.gov databases were searched up to March 4, 2018.

Study Selection:

A search was performed of clinical trials assessing the anxiolytic effect of omega-3 PUFAs in humans, in either placebo-controlled or non-placebo-controlled designs. Of 104 selected articles, 19 entered the final data extraction stage.

Data Extraction and Measures:

Two authors independently extracted the data according to a predetermined list of interests. A random-effects model meta-analysis was performed and this study was conducted based on Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.

Main Outcomes and Measures:

Changes in the severity of anxiety symptoms after omega-3 PUFA treatment.

Results:

In total, 1203 participants with omega-3 PUFA treatment (mean age, 43.7 years; mean female proportion, 55.0%; mean omega-3 PUFA dosage, 1605.7 mg/d) and 1037 participants without omega-3 PUFA treatment (mean age, 40.6 years; mean female proportion, 55.0%) showed an association between clinical anxiety symptoms among participants with omega-3 PUFA treatment compared with control arms (Hedges g, 0.374; 95% CI, 0.081-0.666; P = .01). Subgroup analysis showed that the association of treatment with reduced anxiety symptoms was significantly greater in subgroups with specific clinical diagnoses than in subgroups without clinical conditions. The anxiolytic effect of omega-3 PUFAs was significantly better than that of controls only in subgroups with a higher dosage (at least 2000 mg/d) and not in subgroups with a lower dosage (<2000 mg/d).

Conclusions and Relevance:

This review indicates that omega-3 PUFAs might help to reduce the symptoms of clinical anxiety. Further well-designed studies are needed in populations in whom anxiety is the main symptom.

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center